{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonsmall+Cell+Lung+Cancer%2C+Stage+IV&page=21", "query": { "condition": "Nonsmall Cell Lung Cancer, Stage IV", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1119, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonsmall+Cell+Lung+Cancer%2C+Stage+IV&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonsmall+Cell+Lung+Cancer%2C+Stage+IV&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T15:22:40.852Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01096381", "title": "Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Cardiovascular Complications", "Colorectal Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2010-03", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2012-02-27", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01096381" }, { "nct_id": "NCT07756645", "title": "A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "ABBV-1480", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab- Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2026-09-22", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 1, "location_summary": "Fort Wayne, Indiana", "locations": [ { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07756645" }, { "nct_id": "NCT00309998", "title": "Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "70 Years to 120 Years" }, "enrollment_count": 50, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309998" }, { "nct_id": "NCT00438204", "title": "Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2006-05", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00438204" }, { "nct_id": "NCT04166487", "title": "Plasma-Adapted First-Line Pembro In NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC Stage IV", "Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "PEMETREXED", "type": "DRUG" }, { "name": "CARBOPLATIN", "type": "DRUG" }, { "name": "PACLITAXEL", "type": "DRUG" }, { "name": "InVision", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Julia K. Rotow, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-01-13", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Brighton, Massachusetts • South Weymouth, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Brighton", "state": "Massachusetts" }, { "city": "South Weymouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166487" }, { "nct_id": "NCT03307785", "title": "Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Metastatic Cancer", "Advanced Cancer", "Solid Tumor", "Non Small Cell Lung Cancer Metastatic", "Non Small Cell Lung Cancer Stage IIIB", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "Carboplatin-Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TSR-022", "type": "DRUG" }, { "name": "Carboplatin-Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin-Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-10-12", "completion_date": "2024-12-11", "has_results": true, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03307785" }, { "nct_id": "NCT03409614", "title": "Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "REGN2810", "type": "DRUG" }, { "name": "REGN2810/chemo/ipi", "type": "DRUG" }, { "name": "Chemotherapy", "type": "OTHER" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 789, "start_date": "2018-03-06", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 9, "location_summary": "Rancho Mirage, California • Riverside, California • Whittier, California + 6 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409614" }, { "nct_id": "NCT00019825", "title": "Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Lung Cancer", "Malignant Mesothelioma", "Metastatic Cancer" ], "interventions": [ { "name": "decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019825" }, { "nct_id": "NCT02580708", "title": "Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rociletinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-09-30", "completion_date": "2016-06-27", "has_results": false, "last_update_posted_date": "2018-10-02", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 4, "location_summary": "St Louis, Missouri • Charlotte, North Carolina • Nashville, Tennessee + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02580708" }, { "nct_id": "NCT00061646", "title": "Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "ABT-510/Thrombospondin-1 mimetic", "type": "DRUG" }, { "name": "Carboplatin/Taxol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2003-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-08-14", "last_synced_at": "2026-10-24T15:22:40.852Z", "location_count": 4, "location_summary": "Miami, Florida • Chicago, Illinois • Memphis, Tennessee + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061646" } ] }